Hirose, Chiemi
Fujii, Hironori
Iihara, Hirotoshi
Ishihara, Masashi
Nawa-Nishigaki, Minako
Kato-Hayashi, Hiroko
Ohata, Koichi
Sekiya, Kumiko
Kitahora, Mika
Matsuhashi, Nobuhisa
Takahashi, Takao
Okuda, Kumiko
Naruse, Masayo
Ishihara, Takuma
Sugiyama, Tadashi
Yoshida, Kazuhiro
Suzuki, Akio
Article History
Received: 11 November 2019
Accepted: 27 March 2020
First Online: 12 April 2020
Compliance with ethical standards
:
: K. Yoshida has received honoraria for lectures from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly and Company, Yakult Honsha Co., Ltd., Merck Sharp & Dohmegrants Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Johnson & Johnson Co., Ltd., Covidien Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., Asahi Kasei Co., Ltd., Tsumura Co., Ltd., EA Pharma Co., Ltd., Bayer Yakuhin Co., Ltd., Olympus Co., Ltd., Terumo Co., Ltd., Bristol-Myers Squibb Co., Ltd., Denka Co., Ltd., Teijin Co., Ltd., SBI Pharmaceuticals Co., Ltd., Intuitive Surgical Co., Ltd., and Novartis Pharma K.K., Pfizer Inc., and research funding from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Eli Lilly and Company, Yakult Honsha Co., Ltd., Merck Sharp & Dohmegrants Co., Ltd., Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., Merck Serono Co., Ltd., Johnson & Johnson Co., Ltd., Covidien Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Sanofi K.K., Nippon Kayaku Co., Ltd., Asahi Kasei Co., Ltd., Tsumura Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Co., Ltd., Toyama Chemical Co., Ltd., Kinetic Concepts Co., Ltd., Abbott Japan Co., Ltd., and Toray Industries, Co., Ltd. outside the submitted work.T. Takahashi has received honoraria for lectures from Takeda Pharmaceutical Co., Ltd. and Sanofi Co., Ltd. The other authors have no conflicts of interest.